J Fanning1. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical College of Ohio, Toledo, Ohio 43614-5809, USA.
Abstract
OBJECTIVES: The aim of this study was to determine long-term survival and late complications of intermediate risk endometrial cancer (Stage IG3, IC, and II) treated with full lymphadenectomy and brachytherapy without teletherapy. METHODS: Two-hundred sixty-five consecutive patients underwent surgical staging for endometrial cancer consisting of hysterectomy, oophorectomy, and bilateral pelvic and periaortic lymphadenectomy. Sixty-six patients had intermediate risk endometrial cancer (Stage IG3, IC, and II) and received postoperative brachytherapy without teletherapy. Mean age was 68 years and mean weight was 188 lb. Seventy-seven percent had associated medical illness. RESULTS: At a mean follow-up of 4.4 years, Kaplan-Meier estimated 5-year progression free survival is 97%. Two patients (3%) developed distant recurrence (abdomen, lungs) with no vaginal or pelvic recurrence. Major complications occurred in 6% of patients. CONCLUSIONS: Complete lymphadenectomy with brachytherapy without teletherapy for intermediate risk endometrial cancer results in excellent progression-free survival and minimal major morbidity. Copyright 2001 Academic Press.
OBJECTIVES: The aim of this study was to determine long-term survival and late complications of intermediate risk endometrial cancer (Stage IG3, IC, and II) treated with full lymphadenectomy and brachytherapy without teletherapy. METHODS: Two-hundred sixty-five consecutive patients underwent surgical staging for endometrial cancer consisting of hysterectomy, oophorectomy, and bilateral pelvic and periaortic lymphadenectomy. Sixty-six patients had intermediate risk endometrial cancer (Stage IG3, IC, and II) and received postoperative brachytherapy without teletherapy. Mean age was 68 years and mean weight was 188 lb. Seventy-seven percent had associated medical illness. RESULTS: At a mean follow-up of 4.4 years, Kaplan-Meier estimated 5-year progression free survival is 97%. Two patients (3%) developed distant recurrence (abdomen, lungs) with no vaginal or pelvic recurrence. Major complications occurred in 6% of patients. CONCLUSIONS: Complete lymphadenectomy with brachytherapy without teletherapy for intermediate risk endometrial cancer results in excellent progression-free survival and minimal major morbidity. Copyright 2001 Academic Press.
Authors: J L Guinot; J Pérez-Calatayud; J M Azcoaga; I Herruzo; C Bodineau; A Rovirosa; V Crispín; P Galán; E González-Patiño; J Pérez-Regadera; A Polo Journal: Clin Transl Oncol Date: 2012-04 Impact factor: 3.405
Authors: Leszek Gottwald; Piotr Pluta; Janusz Piekarski; Michał Spych; Katarzyna Hendzel; Katarzyna Topczewska-Tylinska; Dariusz Nejc; Robert Bibik; Jerzy Korczyński; Aleksandra Ciałkowska-Rysz Journal: Arch Med Sci Date: 2010-12-29 Impact factor: 3.318
Authors: A Talhouk; M K McConechy; S Leung; H H Li-Chang; J S Kwon; N Melnyk; W Yang; J Senz; N Boyd; A N Karnezis; D G Huntsman; C B Gilks; J N McAlpine Journal: Br J Cancer Date: 2015-06-30 Impact factor: 7.640